signal/raiseTrack rounds
SeedHealthtech & bio · Nagoya

PulmoGate raises ¥330m seed round led by Beyond Next Ventures for lung disease AI

The Nagoya University spinout, founded a year ago, is preparing to launch remote specialist second opinions for interstitial lung disease while it develops diagnostic and treatment-planning AI. Teijin Pharma also invested.

s/rFunding deskEast Asia · 3 min read

PulmoGate, a medical AI startup spun out of Nagoya University, said on 18 November 2026 that it had raised about ¥330m (about $2.1m) in a seed round led by Beyond Next Ventures.

Teijin Pharma, Mitsubishi UFJ Capital and STATION Ai Central Japan No. 2 Investment Limited Partnership, a fund run jointly by STATION Ai and DeepCore, also took part. The four investors subscribed for new shares in a third-party allotment. The company did not disclose a valuation.

PulmoGate focuses on interstitial lung disease (ILD), a group of conditions in which the lungs become inflamed and scarred. It plans to use the money to widen access to an online second-opinion service and to push its diagnostic AI towards clinical validation and regulatory approval.

“一人ひとりに、最適な治療を。当社は間質性肺疾患について、診断から治療、そしてリハビリまでの様々な臨床課題を解決するソリューションの開発を目指します。”Tomo Tominaga, Representative Director and CEO, PulmoGate

What PulmoGate does

A multidisciplinary discussion is the recommended route to an ILD diagnosis and treatment plan, in which respiratory physicians, radiologists and, where needed, pathologists review a case together. The company said few hospitals can bring all of those specialists together under one roof.

PulmoGate's first service is meant to fill that gap. It is preparing to formally launch online second opinions for partner hospitals, using remote multidisciplinary discussion on a system inherited from the PROMISE trial, a Nagoya University-led study of holding such discussions online. The attending physician receives a report setting out candidate diagnoses, suggested extra tests and points to weigh when choosing treatment.

In parallel, the company is developing three further products: a diagnostic AI for idiopathic pulmonary fibrosis (IPF), the most common progressive form of ILD; an AI to help choose treatment for each patient; and an app to track patients at home and support respiratory rehabilitation. PulmoGate said all three are at the research stage and have not been approved as medical devices. It aims to connect them so that information from diagnosis and from patients' progress after treatment feeds into later treatment decisions.

The release cited Japanese health ministry data ranking ILD as the 11th leading cause of death in Japan, with prevalence roughly doubling from 656 to 1,301 per 100,000 people between 2015 and 2023. Five-year survival is 59.9% across all ILD and 32.1% for IPF, according to a study the company cited.

Who is behind it

PulmoGate was founded in November 2025 and is based at the STATION Ai startup hub in Nagoya. It was set up to commercialise ILD research by Dr Taiki Furukawa, deputy director of the Medical IT Center at Nagoya University Hospital, who is a co-founder, director and chief medical officer. The chief executive is Tomo Tominaga, who according to Beyond Next Ventures previously built a preventive healthcare business, grew it and led it through a sale. The company did not give a headcount.

Tokyo-based Beyond Next Ventures said it had worked with Furukawa since 2022 on turning the research into a business, including business planning and forming the management team. In the release, its partner Katsuya Hashizume said only a small share of ILD patients currently receive a multidisciplinary diagnosis, and described Furukawa's AI research, the PROMISE trial data and its network of specialists as the base for changing that.

Teijin Pharma president Masaki Taneda pointed to the large unmet medical need in ILD. Ryo Kato of Mitsubishi UFJ Capital said the firm backed the company's approach of covering everything from diagnosis to rehabilitation. Junya Nakajima of STATION Ai said the firm had come to know Furukawa through the Tongali GAP fund programme it helps run before deciding to invest. Earlier funding amounts were not disclosed.

What the money is for

PulmoGate listed three uses for the funds. The first is increasing the number of hospitals that offer ILD second opinions through its remote platform. The second is building up the team that will validate the diagnostic AI's performance, run clinical evaluations and handle regulatory work. The third is research and clinical evaluation of the treatment-strategy AI and of the home monitoring and rehabilitation tools.

In his comment, Tominaga said the first priorities are a full rollout of the online second-opinion service and the development and validation of AI to support diagnosis and treatment. Business magazine Project Design also reported the round, with the same amount, investors and planned uses of the money.

Company website: pulmogate.com